SEC Company Response from Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704) (CLRB) — Nov 30, 2011
Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)
Date: Nov. 30, 2011 · CIK: 0001279704 · Accession: 0001144204-11-067636
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-175284
Letter
Unassociated Document
Harry S. Palmin hpalmin@novelos.com
President and CEO
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
November 30, 2011
Re:
Novelos Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-175284)
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Novelos Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the Company’s Registration Statement on Form S-1, as amended (File No. 333-175284) (the “Registration Statement”), be accelerated so that the Registration Statement will become effective at 4:30 p.m., Eastern time, on Wednesday, November 30, 2011, or as soon as practicable thereafter.
The Company acknowledges that:
·
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Novelos Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
Harry S. Palmin
hpalmin@novelos.com
President and CEO
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
November 30, 2011
Re:
Novelos Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-175284)
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Novelos Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the Company’s Registration Statement on Form S-1, as amended (File No. 333-175284) (the “Registration Statement”), be accelerated so that the Registration Statement will become effective at 4:30 p.m., Eastern time, on Wednesday, November 30, 2011, or as soon as practicable thereafter.
The Company acknowledges that:
·
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Novelos Therapeutics, Inc.
By: /s/ Harry S. Palmin
Harry S. Palmin, President and CEO
Novelos Therapeutics, Inc. One Gateway Center, Suite 504 Newton, MA 02458 617.244.1616 Fax 964.6331